On course to publish our scientific research and findings.
We are committed to publishing the results from our pre-clinical and clinical research in collaboration with the scientists, physicians, researchers and others with whom we collaborate at medical meetings and in peer-reviewed publications.
ME-344, a novel isoflavone mitochondrial inhibitor, in combination with venetoclax constitutes a new metabolism-targeted approach to overcome resistance to Bcl-2 inhibition and standard of care treatment in AML, AACR Annual Meeting 2022
A Phase 1 Dose-Escalation Study of the Oral CDK Inhibitor Voruciclib in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia (AML): Preliminary Results of the Completed Dose Escalation Stage in AML, 63rd ASH Annual Meeting, December 2021
A Novel Isoflavone, ME-344, Enhances Venetoclax Antileukemic Activity Against AML via Suppression of Oxidative Phosphorylation and Purine Biosynthesis, 63rd ASH Annual Meeting, December 2021
Voruciclib, a CDK9 inhibitor, downregulates MYC and inhibits proliferation of KRAS mutant cancers in preclinical models, AACR Annual Meeting 2021
|Aug 2020||Journal Papers||
Zhang, et al. Voltage-Dependent Anion Channels Influence Cytotoxicity of ME-344, a Therapeutic Isoflavone. J Pharmacol Exp Ther. 2020 Aug;374(2):308-318.
|Feb 2020||Journal Papers||
Luedtke, et al. Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia. Signal Transduct Target Ther. 2020 Feb 26;5(1):17.
|Jan 2020||Journal Papers||
Quintela-Fandino, et al. Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer. Clin Cancer Res. 2020 Jan 1;26(1):35-45.
|Aug 2019||Journal Papers||
Zhang, et al. Isoflavone ME-344 Disrupts Redox Homeostasis and Mitochondrial Function by Targeting Heme Oxygenase 1. Cancer Res. 2019 Aug 15;79(16):4072-4085.
A randomized phase 0 trial of the mitocondrial inhibitor ME344 or placebo added to the antiangiogenic (Aa) bevacizumab in early HER2-negative breast cancer (E-HERNEBC), ASCO Annual Meeting, June 2019
|Jan 2019||Journal Papers||
Zhang, et al. Pharmacology of ME-344, a novel cytotoxic isoflavone. Adv Cancer Res. 2019;142:187-207
Voruciclib, an Oral, Selective CDK9 Inhibitor, Enhances Cell Death Induced by the Bcl-2 Selective Inhibitor Venetoclax in Acute Myeloid Leukemia
Abrogation of resistance against bevacizumab (Bev) by mitochondrial inhibition: a phase 0 randomized trial of Bev plus ME344 or placebo in early HER2-negative breast cancer (HERNEBC), ASCO Annual Meeting, June 2018
|Dec 2017||Journal Papers||
Dey, et al. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition. Sci Rep. 2017 Dec 21;7(1):18007.
|Jan 2017||Journal Papers||
Diamond, et al. Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers. Invest New Drugs. 2017 Oct;35(5):627-633.
|Aug 2016||Journal Papers||
Jeyaraju, et al. A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia. Oncotarget. 2016 Aug 2;7(31):49777-49785.
|Aug 2016||Journal Papers||
Manevich, et al. Redox Signaling and Bioenergetics Influence Lung Cancer Cell Line Sensitivity to the Isoflavone ME-344. J Pharmacol Exp Ther. 2016 Aug;358(2):199-208.
|Jul 2016||Journal Papers||
Eliades, et al. A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors. Cancer Biol Ther. 2016 Jul 2;17(7):778-84.
|Jun 2016||Journal Papers||
Navarro, et al. Targeting Tumor Mitochondrial Metabolism Overcomes Resistance to Antiangiogenics. Cell Rep. 2016 Jun 21;15(12):2705-18.
Voruciclib, a clinical stage CDK inhibitor sensitizes triple negative breast cancer xenografts to proteasome inhibition. AACR Annual Meeting, April 2016
|Nov 2015||Journal Papers||
Paiva, et al. Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells. PLoS One. 2015 Nov 25;10(11)
Phase I trial of the CDK 4/6 inhibitor, P1446A-05 (voruciclib) in combination with the BRAF inhibitor (BRAFi), vemurafenib in advanced, BRAF-mutant melanoma. ASCO Annual Meeting, June 2015
ME-344, a Novel Isoflavone with Activity as a Mitochondrial Oxygenase Inhibitor. AACR Annual Meeting, Apr 2015
|Apr 2015||Journal Papers||
Bendell, et al. Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors. Cancer. 2015 Apr 1;121(7):1056-63.
|Jan 2015||Journal Papers||
Lim, et al. Anti-cancer analogues ME-143 and ME-344 exert toxicity by directly inhibiting mitochondrial NADH: ubiquinone oxidoreductase (Complex I). Am J Cancer Res. 2015 Jan 15;5(2):689-701.
|Aug 2011||Journal Papers||
Alvero, et al. Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells. Mol Cancer Ther. 2011 Aug;10(8):1385-93.
|Jul 2009||Journal Papers||
Alvero, et al. NV-128, a novel isoflavone derivative, induces caspase-independent cell death through the Akt/mammalian target of rapamycin pathway. Cancer. 2009 Jul 15;115(14):3204-16